• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Milestone Pharmaceuticals Inc.

    4/30/26 4:07:05 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MIST alert in real time by email
    DEFA14A 1 tm261628d4_defa14a.htm DEFA14A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934

     

    Filed by the Registrant x

     

    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨Preliminary Proxy Statement
      
    ¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
      
    ¨Definitive Proxy Statement
      
    xDefinitive Additional Materials
      
    ¨Soliciting Material under §240.14a-12

     

    MILESTONE PHARMACEUTICALS INC.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    xNo fee required.
    ¨Fee paid previously with preliminary materials.
    ¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

     

    GRAPHIC

    Milestone Pharmaceuticals Inc. Shareholder Meeting Notice 026A8A Fold Fold IMPORTANT ANNUAL MEETING INFORMATION Important Notice Regarding the Availability of Proxy Materials for the 2026 Annual Meeting of Shareholders of Milestone Pharmaceuticals Inc. to be Held on June 10, 2026 We are using the U.S. “notice-and-access” system for delivery of the proxy materials relating to this year’s annual meeting of shareholders. Under Securities and Exchange Commission rules, instead of receiving a paper copy of the proxy materials you are receiving this notice that the proxy materials for the annual meeting of shareholders are available on the Internet. Follow the instructions below to view the materials and vote online or request a paper copy. The items to be voted on and the location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The proxy statement and annual report to shareholders are available at: www.envisionreports.com/milestone2026 Easy Online Access — A Convenient Way to View Proxy Materials and Vote When you go online to view the proxy materials, you can also vote your shares. Step 1: Go to www.envisionreports.com/milestone2026 to view the proxy materials. Step 2: Click on Cast Your Vote. Step 3: Follow the instructions on the screen to log in. Step 4: Make your selection as instructed on each screen to select delivery preferences and vote. You may also access our proxy materials in the investor relations section of our website at www.milestonepharma.com and under our issuer profile at www.sedarplus.com. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Obtaining a Paper Copy of the Proxy Materials – If you want to receive a paper copy of the proxy materials, you must request one. There is no charge to you for requesting a paper copy. Please make your request for a paper copy as instructed on the reverse side on or before May 27, 2026 to facilitate timely delivery. Vote by Internet • Go to www.envisionreports.com/milestone2026 • Or scan the QR code with your smartphone • Follow the steps outlined on the secure website Mr A Sample Designation (if any) Add1 Add2 add3 add4 add5 add6 C1234567890 XXX 000001 CPUQC01.E.INT/000001/i1234 UMPQ ENDORSEMENT_LINE______________ SACKPACK_____________ C1234567890 XXX

    GRAPHIC

    Milestone Pharmaceuticals Inc. Shareholder Meeting Notice Milestone Pharmaceuticals Inc. 2026 Annual Meeting of Shareholders will be held on June 10, 2026 via a virtual meeting portal at https://meetnow.global/MUAPKKN. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations, where applicable. The Board of Directors recommends that you vote FOR Proposals 1, 2, 3 and 4. 1. Election of Directors. Nominees: Stuart M. Duty Seth H.Z. Fischer Lisa M. Giles Joseph Oliveto Joseph C. Papa Andrew R. Saik Michael Tomsicek Robert J. Wills, Phd 2. Appoint PricewaterhouseCoopers LLP as auditors. 3. Approve the Company’s 2019 Equity Incentive Plan, as amended, to increase the number of shares authorized for issuance by 6.8 million shares. 4. Advisory approval of the compensation paid to our named executive officers. PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must vote online, by telephone or request a paper copy of the proxy materials to receive a proxy card. Your online or telephonic vote or completed proxy card must be received by 5:00 p.m. (Eastern Time) on June 8, 2026 or, if the meeting is adjourned or postponed, your online or telephonic vote or completed proxy card must be received at least 48 hours, excluding Saturdays, Sundays and applicable holidays, before the reconvened meeting. If you wish to appoint a person to attend and vote at the meeting on your behalf, please follow the instructions online or on the proxy card to appoint such person. Please review the proxy materials before voting. For directions and additional information regarding attending the meeting, please consult the proxy materials or contact Investor Relations at ir@milestonepharma.com. Here’s how to order a paper copy of the proxy materials and select a future delivery preference: Paper copies: Current and future paper delivery requests can be submitted via the telephone, Internet or email options below. Email copies: Current and future email delivery requests must be submitted via the Internet following the instructions below. If you request an email copy of current proxy materials you will receive an email with a link to the materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a set of proxy materials. g Internet – Go to www.envisionreports.com/milestone2026. Click Cast Your Vote. Follow the instructions to log in and order a paper copy of the current proxy materials and submit your preference for email or paper delivery of future proxy materials. g Telephone – Call us free of charge at within North America - 1-866-962-0498 or direct, from Outside of North America - (514) 982-8716 and follow the instructions to log in and order a paper copy of the proxy materials by mail for the current meeting. You can also submit a preference to receive a paper copy for future meetings. g Email – Send email to service@computershare.com with “Proxy Materials Milestone Pharmaceuticals Inc.” in the subject line. Include in the message your full name and address, plus the number located in the shaded bar on the reverse side, and state in the email that you want a paper copy of current proxy materials. You can also state your preference to receive a paper copy for future meetings. g If you have questions about electronic delivery of proxy materials, you can also call Milestone Investor Relations at (514) 336-0444 or send an email to ir@milestonepharma.com. To facilitate timely delivery, all requests for a paper copy of the proxy materials must be received on or before May 27, 2026. 026A9A

     

    Get the next $MIST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MIST

    DatePrice TargetRatingAnalyst
    4/10/2026$6.00Strong Buy
    Raymond James
    12/15/2025$8.00Hold → Buy
    TD Cowen
    9/11/2025$4.00Overweight
    Wells Fargo
    6/5/2025$5.00Buy
    H.C. Wainwright
    8/22/2024$9.00Buy
    Rodman & Renshaw
    6/20/2023$8.00 → $4.00Buy → Hold
    Jefferies
    4/22/2022$8.00 → $10.00Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $MIST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Oliveto Joseph

    4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

    4/20/26 4:06:18 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Sandoval David I.

    3 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

    3/23/26 6:51:28 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by Chief Medical Officer Bharucha David

    4/A - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

    2/5/26 4:30:19 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MIST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

    MONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ to take place on Tuesday, May 19, 2026 in New York. A live webcast of the fireside chat will be available to conference participants on May 19th at 3:00pm ET. The webcast is available to watch both live and replay for approximately 90-days following the presentation on the News & Events section of Milestone's website www.milestonepharma.com. If you

    5/14/26 8:30:00 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

    CARDAMYST™ (etripamil) nasal spray launch for PSVT is gaining traction; breadth of unique prescribers supports potential future adoptionExpress Scripts national formulary coverage secured as company makes progress toward broad patient accessAtrial Fibrillation-RVR Phase 3 registration trial initiated: patient enrollment to begin in H2 2026Strong balance sheet of $184.2M provides runway into H2 2027 to fund commercial and operational prioritiesCompany to host investor call and webcast at 8:30am ET today MONTREAL and CHARLOTTE, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of

    5/13/26 7:11:06 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026

    MONTREAL and CHARLOTTE, May 06, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report financial results for the first quarter ended March 31, 2026, and provide a business update before the market open. The announcement will be followed by a conference call and webcast for investors at 8:30am ET. Conference Details: Conference Date:Wednesday, May 13, 2026Conference Time:8:30am ETConference Dial-in:1-877-407-0792International Dial-in:1-201-689-8263Conference ID:13760062Webcast link:Click here. Participants can use Guest

    5/6/26 8:00:00 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MIST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on Milestone Pharmaceuticals with a new price target

    Raymond James initiated coverage of Milestone Pharmaceuticals with a rating of Strong Buy and set a new price target of $6.00

    4/10/26 8:32:45 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Milestone Pharmaceuticals upgraded by TD Cowen with a new price target

    TD Cowen upgraded Milestone Pharmaceuticals from Hold to Buy and set a new price target of $8.00

    12/15/25 10:09:22 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Milestone Pharmaceuticals with a new price target

    Wells Fargo initiated coverage of Milestone Pharmaceuticals with a rating of Overweight and set a new price target of $4.00

    9/11/25 8:45:07 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MIST
    SEC Filings

    View All

    SEC Form EFFECT filed by Milestone Pharmaceuticals Inc.

    EFFECT - Milestone Pharmaceuticals Inc. (0001408443) (Filer)

    5/26/26 12:15:18 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Milestone Pharmaceuticals Inc.

    S-3 - Milestone Pharmaceuticals Inc. (0001408443) (Filer)

    5/13/26 5:28:27 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Milestone Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)

    5/13/26 7:23:09 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MIST
    Leadership Updates

    Live Leadership Updates

    View All

    Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

    MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval's appointment comes as Milestone launches CARDAMYST™ (etripamil) nasal spray, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025. He will serve as a member of Milestone's executive leadership team and will provide business-focused legal counsel across all

    2/10/26 8:00:00 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

    Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

    4/10/25 8:30:00 AM ET
    $ACOG
    $CBAY
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

    MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors ("Board"), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, transformation, and strategic M&A transactions, including as former Chairman and CEO of Bausch + Lomb, Bausch Health and Perrigo and as a director of SparingVision and Candel Therapeutics. He brings bro

    9/4/24 8:00:00 AM ET
    $CADL
    $EBS
    $MIST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $MIST
    Financials

    Live finance-specific insights

    View All

    Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

    CARDAMYST™ (etripamil) nasal spray launch for PSVT is gaining traction; breadth of unique prescribers supports potential future adoptionExpress Scripts national formulary coverage secured as company makes progress toward broad patient accessAtrial Fibrillation-RVR Phase 3 registration trial initiated: patient enrollment to begin in H2 2026Strong balance sheet of $184.2M provides runway into H2 2027 to fund commercial and operational prioritiesCompany to host investor call and webcast at 8:30am ET today MONTREAL and CHARLOTTE, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of

    5/13/26 7:11:06 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026

    MONTREAL and CHARLOTTE, May 06, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report financial results for the first quarter ended March 31, 2026, and provide a business update before the market open. The announcement will be followed by a conference call and webcast for investors at 8:30am ET. Conference Details: Conference Date:Wednesday, May 13, 2026Conference Time:8:30am ETConference Dial-in:1-877-407-0792International Dial-in:1-201-689-8263Conference ID:13760062Webcast link:Click here. Participants can use Guest

    5/6/26 8:00:00 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT

    FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic PSVT to sinus rhythm and did so more than 3x faster compared with placeboCARDAMYST launch execution on track with positive initial engagement in the product from healthcare providers and payers $200 million pro forma cash supports strong launch and operating runway into late 2027; includes $106 million of cash at year-end and net proceeds from subsequent financing activities1Company to host investor call and webcast at 8:30am ET today MONTREAL and CHARLOTTE, N.C., March 20, 2026 (GLOBE

    3/20/26 7:12:14 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MIST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Milestone Pharmaceuticals Inc.

    SC 13G/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

    10/29/24 4:30:20 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Milestone Pharmaceuticals Inc.

    SC 13D/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

    7/16/24 6:06:24 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Milestone Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

    2/14/24 8:56:08 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care